Immunologic Factors clinical trials at UC Health

• Cell therapy to Treat Patients with COVID-19

  open to eligible people ages 18 years and up

  This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

  at UC Davis UC Irvine

Last updated: November 20, 2020